FINWIRES · TerminalLIVE
FINWIRES

$SNY

37 stories mentioning SNYUpdated just now

Every FINWIRES story that references SNY, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Premarket Thursday

Healthcare stocks were mixed premarket Thursday, with the iShares Biotechnology ETF (IBB) down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) 0.1% higher.Agilent Technologies (A) stock was up more than 12% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Zenas BioPharma (ZBIO) shares were up more than 1% after the company said it submitted a biologics license application to the US Food and Drug Administration for obexelimab in immunoglobulin G4-related disease, a chronic fibro-inflammatory disease affecting multiple organ systems.Sanofi (SNY) has been granted US Food and Drug Administration priority review for a new drug application for venglustat for the treatment of type 3 Gaucher disease, a rare disorder, the company said. Sanofi shares were 0.8% lower pre-bell.

$A$IBB$SNY$XLV$ZBIO
Asia Markets

European Equities Traded in US as ADRs Rise in Wednesday Trading

European equities traded in the US as American depositary receipts rose Wednesday with the S&P Europe Select ADR Index gaining 1.9% to 1,858.59.From continental Europe, the gainers were led by lender Banco Bilbao Vizcaya Argentaria (BBVA) and biopharmaceutical company Grifols (GRFS), which rose 3.5% and 3.3%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and medical device maker EDAP TMS (EDAP), which were up 2.4% and 0.6%, respectively.The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and telecommunications company Nokia (NOK), which fell 3% and 1.4%, respectively. They were followed by internet advertising firm Criteo (CRTO) and software company SAP (SAP), which were down 1% and 0.9%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which climbed 7.1% and 4%, respectively. They were followed by lenders Barclays (BCS) and Lloyds Banking Group (LYG), which each rose 3.4%.The decliners from the UK and Ireland were led by oil and gas companies BP (BP) and Shell (SHEL), which lost 1.3% and 1%, respectively. They were followed by biotech firm Trinity Biotech (TRIB) and tobacco company British American Tobacco (BTI), down 0.9% and 0.5%, respectively.

$BBVA$BCS$BDRX$BP$BTI$CRTO$EDAP$EQNR$GRFS$LYG$NOK$SAP$SHEL$SLN$SNY$TRIB
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.4%.The iShares Biotechnology ETF (IBB) rose 1.6%.In corporate news, Sanofi (SNY) said Monday it will invest 294 million Canadian dollars ($216 million) to expand its global AI Centre of Excellence in Toronto in a bid to accelerate the development and delivery of medicines. Its shares were down past 5%.Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Eli Lilly (LLY) shares added 0.7% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Vanda Pharmaceuticals (VNDA) shares jumped past 7% after it said Monday its motion sickness drug Nereus is now commercially available in the US.

$AMGN$LLY$SNY$VNDA
Sectors

Sector Update: Health Care

Health care stocks declined late Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.4%.The iShares Biotechnology ETF (IBB) rose 1.6%.In corporate news, Sanofi (SNY) said Monday it will invest 294 million Canadian dollars ($216 million) to expand its global AI Centre of Excellence in Toronto in a bid to accelerate the development and delivery of medicines. Shares were down 6%.

$SNY
Wire

Sanofi Plans $216 Million AI Center Expansion in Toronto

Sanofi (SNY) said Monday it will invest 294 million Canadian dollars ($216 million) to expand its global AI Centre of Excellence in Toronto in a bid to accelerate the development and delivery of medicines.The expansion will create 50 new jobs focused on the designing and deployment of advanced AI tools, according to a statement.The expansion is also supported by a conditional grant of up to CA$5 million from the Invest Ontario Fund, the company said.Shares of Sanofi were down 6% in Monday trading.Price: $43.30, Change: $-2.78, Percent Change: -6.03%

$SNY
Asia Markets

European Equities Traded in the US as American Depositary Receipts Start Week Lower

European equities traded in the US as American depositary receipts kicked off the week lower late Monday morning, falling 0.70% to 1,803.50 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company argenx (ARGX), which climbed 8.1% and 1.9% respectively. They were followed by petroleum refiner Equinor (EQNR) and biopharmaceutical company Grifols (GRFS), which advanced 1.8% and 1.5% respectively.The decliners from continental Europe were led by pharmaceutical company Sanofi (SNY) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which dropped 5.5% and 4.2% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which lost 3.3% and 1% respectively.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which rose 9.2% and 2.8% respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which were up 2.3% and 2.2% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and cruise line operator Carnival (CUK), which fell 2.2% and 1.6% respectively. They were followed by pharmaceutical company GSK (GSK) and biotech firm Trinity Biotech (TRIB), which were down 1.2% and 0.4% respectively.

$AKTX$AMRN$ARGX$AUTL$BBVA$BDRX$CLLS$CUK$EDAP$EQNR$GRFS$GSK$NCNA$SNY$SQNS$TRIB
Research

Morgan Stanley Downgrades Sanofi to Equalweight From Overweight, Adjusts Price Target to $52 From $55

Sanofi (SNY) has an average rating of overweight and mean price target of $53.92, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$SNY
Wire

Regeneron's Eylea Franchise on 'Solid Footing' Despite HD Sales Miss in Q1, Oppenheimer Says

Regeneron Pharmaceuticals' (REGN) Q1 results reflected mixed trends, as weaker-than-expected sales of high-dose Eylea weighed on shares, though the broader franchise remains "on solid footing," Oppenheimer said in a note Wednesday.The biotechnology company posted non-GAAP earnings of $9.47 per diluted share, surpassing analyst expectations, but the stock faced downward pressure after Eylea HD recorded $468 million in sales, below the $490 million consensus, the brokerage said.The Eylea franchise got a boost with the US Food and Drug Administration approval of "extended dosing" intervals for HD in wet age-related macular degeneration and diabetic macular edema, according to the note. A decision on a pre-filled syringe is expected in Q2 and Oppenheimer said label expansion for HD could support adoption and help offset market share pressure.Dupixent remains a "key growth driver," supported by "durable demand" and new indications, including chronic spontaneous urticaria and allergic fungal rhinosinusitis, according to the note.Despite competition, the company's outlook is balanced, supported by Dupixent growth, expanding Eylea HD uptake, and expected higher collaboration profits with Sanofi (SNY), the brokerage said.Oppenheimer maintained an outperform rating on Regeneron, with a price target of $865.Shares of Regeneron were up more than 3% in Thursday trading.Price: $707.76, Change: $+21.40, Percent Change: +3.12%

$REGN$SNY
Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.4%.The iShares Biotechnology ETF (IBB) fell 1%.In sector news, the US Food and Drug Administration said it was launching regulatory actions to back the development of psychedelic therapies to treat mental illness. The move builds on President Donald Trump's recent executive order directing the Department of Health and Human Services to accelerate access to treatments for people with serious mental illness, the FDA said.In corporate news, HCA Healthcare's (HCA) Q1 results exceeded market expectations, but the hospital operator said it did not see its usual seasonal lift in admissions amid declines in respiratory activity. Its shares dropped 9%.Organon (OGN) shares surged 32% amid a report that India's Sun Pharmaceutical Industries was planning a $13 billion bid for the company.Compass Pathways (CMPS) shares rose 4.8% after it said Friday the US Food and Drug Administration has granted its rolling review request for its new drug application and selected COMP360 for the Commissioner's National Priority Voucher program for treatment-resistant depression.Sanofi (SNY) priced a 2.3 billion euro ($2.7 billion) offering of notes under its Euro Medium Term Note program. Its shares were down 1.5%.

$CMPS$HCA$OGN$SNY
Sectors

Sector Update: Health Care

Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.4%.The iShares Biotechnology ETF (IBB) fell 1%.In corporate news, Sanofi (SNY) priced a 2.3 billion euro ($2.7 billion) offering of notes under its Euro Medium Term Note program. Its shares were down 1%.

$SNY
Wire

Sanofi Prices $2.7 Billion in Bonds in Three-Part Offering

Sanofi (SNY) priced its 2.3 billion euro ($2.7 billion) offering of notes under its Euro Medium Term Note program.The deal includes 1 billion euros in notes due May 2029 with a 3% coupon, 650 million euros in notes due May 2033 at 3.375%, and 650 million euros in notes due May 2037 at 3.75%, the company said Friday in a statement.Sanofi plans to use the net proceeds for general corporate purposes.Price: $46.95, Change: $-0.59, Percent Change: -1.23%

$SNY
Asia Markets

European Equities Traded in US as ADRs Ease in Thursday Trading

European equities traded in the US as American depositary receipts eased late Thursday morning with the S&P Europe Select ADR Index dropping 0.1% to 1,801.52.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and pharmaceutical company Sanofi (SNY), which rose 6.4% and 2.5%, respectively. They were followed by biopharmaceutical company argenx (ARGX) and medical device maker EDAP TMS (EDAP), which were up 0.7% and 0.6%, respectively.The decliners from continental Europe were led by software firm SAP (SAP) and internet advertising company Criteo (CRTO), which fell 5% and 3.5%, respectively. They were followed by internet browser company Opera (OPRA) and 3D printer company Materialise (MTLS), which were down 3.2% and 3.1%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and hospitality company InterContinental Hotels Group (IHG), which advanced 4.8% and 2.4%, respectively. They were followed by biopharmaceutical company Amarin (AMRN) and telecommunications operator Vodafone Group (VOD), which increased 2% and 1.6%, respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Trinity Biotech (TRIB), which lost 6.4% and 6.2%, respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Akari Therapeutics (AKTX), which dropped 6.1% and 2.6%, respectively.

$AKTX$AMRN$ARGX$BDRX$CRTO$DAVA$EDAP$IHG$MTLS$NOK$OPRA$SAP$SLN$SNY$TRIB$VOD
Sectors

Sector Update: Health Care Stocks Decline Premarket Thursday

Health care stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.7% lower.Thermo Fisher Scientific (TMO) stock was down more than 9% even after the company posted higher fiscal Q1 adjusted earnings and revenue.Sanofi (SNY) shares were up more than 3% after the company reported higher Q1 adjusted earnings and net sales.West Pharmaceutical Services (WST) stock was up more than 16% after the company reported higher Q1 non-GAAP earnings and net sales. West Pharmaceutical Services also issued Q2 outlook above analysts' expectations and raised its 2026 guidance.

$IBB$SNY$TMO$WST$XLV
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Stalled US-Iran Talks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively traded Invesco QQQ Trust (QQQ) was 0.2% lower in Thursday's premarket activity as talks between the US and Iran stalled amid a continued blockage of the Strait of Hormuz.US stock futures were also lower, with S&P 500 Index futures down 0.4%, Dow Jones Industrial Average futures slipping 0.6%, and Nasdaq futures retreating 0.4% before the start of regular trading.US initial jobless claims totaled 214,000, compared with expectations of 210,000 and a prior reading of 208,000.The Chicago Federal Reserve Bank's monthly National Activity Index fell to a reading of minus 0.20 in March from 0.03 in February, compared with expectations for a smaller decrease to minus 0.13 in survey of analysts compiled by Bloomberg as of 7:35 am ET.S&P Global flash estimates of manufacturing and services conditions for April will be released at 9:45 am ET, followed by weekly natural gas stocks at 10:30 am ET.The Kansas City Fed's manufacturing reading for April will be released at 11 am ET.In premarket activity, bitcoin was down by 1.6%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.7% lower, Ether ETF (EETH) retreated by 3.3%, and Bitcoin & Ether Market Cap Weight ETF (BETH) declined by 0.02%.Power Play:EnergyThe iShares US Energy ETF (IYE) gained 0.03%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.4%.Helix Energy Solutions (HLX) stock was up more than 8% before the opening bell after the company agreed to merge with Hornbeck Offshore Services in an all-stock deal to form an integrated offshore services company.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.04%, the Vanguard Health Care Index Fund (VHT) was down 0.3%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) declined by 1.2%.Sanofi (SNY) stock was up more than 3% premarket after the company reported higher Q1 adjusted earnings and sales.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% lower.KB Financial Group (KB) shares were up more than 2% pre-bell after the company reported higher Q1 earnings and revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.04%, while the Vanguard Industrials Index Fund (VIS) gained 0.7% and the iShares US Industrials ETF (IYJ) was down 0.4%.Union Pacific (UNP) stock was up more than 2% before the opening bell after the company reported Q1 earnings and operating revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.3%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.5%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Tesla (TSLA) shares were down more than 2% pre-bell after the company overnight reported Q1 results, with investors focused on its outsized capital expenditure outlook.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.4%, and the iShares US Technology ETF (IYW) was flat, while the iShares Expanded Tech Sector ETF (IGM) was down 0.9%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 0.04% higher, while the iShares Semiconductor ETF (SOXX) rose by 0.9%.Intel (INTC) shares were up more than 1% in Thursday's premarket activity after Tesla (TSLA) Chief Executive Elon Musk said he intends to use Intel's upcoming 14A process to make chips at its Terafab advanced artificial intelligence project in Austin, Texas.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 0.2% to $93.17 per barrel on the New York Mercantile Exchange. Natural gas gained by 0.1% to reach $2.73 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.1%, while the United States Natural Gas Fund (UNG) was 0.4% lower.Gold futures for May were down by 0.4% at $4,734.40 an ounce on the Comex. Silver futures retreated by 3.1% to $76.11 an ounce. SPDR Gold Shares (GLD) was 0.3% lower, and the iShares Silver Trust (SLV) fell by 1.8%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$HLX$IBB$IGM$IGV$INTC$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$KB$PMR$QQQ$RTH$SLV$SNY$SOXX$SPY$TSLA$UNG$UNP$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Research

Research Alert: Dupixent And Newer Drugs Power Sanofi Q1 Beat; Focus Turns To Incoming Ceo

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Sanofi's Q1 2026 results beat consensus, with sales of EUR10.5B (vs. the EUR10.3B consensus) growing 6.2% Y/Y or 13.6% at CER, while its business EPS of EUR1.88 beat the EUR1.80 consensus. Dupixent continued its strong trajectory with 30.8% CER growth, while new launches like Altuviiio grew 42.2% CER on patient switches from older treatments. Sanofi reiterated its 2026 guidance for high-single-digit sales growth at CER and business EPS growth slightly faster than sales, in line with consensus. We expect Dupixent and newer drugs to support the 2026 outlook. We continue to like Dupixent's strong growth and rising contribution from new launches, which should gradually reduce its revenue concentration risk. With limited patent expiry exposure until Dupixent's 2031 cliff, we view the long-term setup as positive. However, we view that near-term sentiment will depend on incoming CEO Belen Garijo's R&D strategy to improve execution and restore confidence after recent disappointing pipeline readouts.

$SNY
Research

BNP Paribas Downgrades Sanofi to Neutral From Outperform, Lowers Price Target to $50 From $59

Sanofi (SNY) has an average rating of overweight and mean price target of $54.32, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$SNY
Asia Markets

European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading

European equities traded in the US as American depositary receipts began the week little changed late Monday morning, edging 0.02% higher to 1,822.16 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and telecommunications company Nokia (NOK), which advanced 26% and 9.3%, respectively. They were followed by furniture maker Natuzzi (NTZ) and biotech firm Evaxion (EVAX), which climbed 7.1% and 3.4%, respectively.The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and brewing company Anheuser-Busch InBev (BUD), which dropped 3.3% and 1.2%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and lender Banco Santander (SAN), which were off 0.9% and 0.8%, respectively.The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Mereo BioPharma Group (MREO), which rose 7% and 4.8%, respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and Bicycle Therapeutics (BCYC), which increased 4.1% and 2.4%, respectively.The decliners from the UK and Ireland were led by biotech company Trinity Biotech (TRIB) and cruise line operator Carnival (CUK), which fell 4.7% and 3.3%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and lender Barclays (BCS), which were down 2.2% and 0.9%, respectively.

$BCS$BCYC$BDRX$BUD$CLLS$CUK$EVAX$MREO$NCNA$NOK$NTZ$SAN$SLN$SNY$TRIB$TRVG

Showing 21-37 of 37

Track with the FINWIRES app suite

FolioX
FolioX
Track SNY in your portfolio
WheelAI
WheelAI
Analyze SNY options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SNY
SNY News | FINWIRES